Recce Pharmaceuticals Receives $2 Million Grant from U.S. Department of Defense for RECCE® 327 Gel
July 16, 2024 08:00 ET
|
Recce Pharmaceuticals
Funding to accelerate development of RECCE® 327 Gel (R327G) for acute treatment of burn wound infections and downstream bacterial complications such as sepsis in a military settingR327G to be...
Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter baumannii
July 10, 2024 08:00 ET
|
Recce Pharmaceuticals
RECCE® 327 (R327) demonstrated significant bactericidal activity against ‘superbug’ Acinetobacter baumannii (A. baumannii) demonstrating 99.99999% log reduction (>7.5 log reduction) in adult human...
Recce Pharmaceuticals Reports Positive Data from Phase I/II Urinary Tract Infection (UTI) / Urosepsis Rapid Infusion Trial of RECCE® 327
July 01, 2024 08:00 ET
|
Recce Pharmaceuticals
Results demonstrate efficacy on bacterial growth in participants injected with RECCE® 327 (R327) at the highest tested dose of 4,000mgNo serious adverse events and clinically significant changes...
Recce Pharmaceuticals Receives Ethics Approval to Broaden RECCE® 327 Gel Trials Across all Topical Bacterial Skin Infections
June 25, 2024 08:00 ET
|
Recce Pharmaceuticals
Positions RECCE® 327 (R327) gel as a potential broad topical therapeutic for all bacterial skin infectionsHuman Research Ethics Committee approval received for Phase II trial of R327 for acute...
Recce Pharmaceuticals Announces Addition of RECCE® 327 to The World Health Organization’s List of Antibacterial Products in Clinical Development
June 20, 2024 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, June 20, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced its primary...
Recce Pharmaceuticals Completes Dosing Additional Cohort in Phase I/II UTI/Urosepsis Rapid Infusion Trial
June 12, 2024 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, June 12, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX:RCE, FSE:R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced it completed...
Recce Pharmaceuticals Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial
May 17, 2024 08:00 ET
|
Recce Pharmaceuticals
First participants (male/female) dosed at 4,000mg over 20 minutes, with remaining subjects to be dosed in the near future - 4,000mg highest dosage to date in this clinical trialRECCE® 327 (R327)...
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study
May 13, 2024 08:00 ET
|
Recce Pharmaceuticals
RECCE® 327 (R327) demonstrated >99% log reduction (>2.5 log reduction) in Mycobacterium abscessus lung infections using a nebulizer delivery methodR327 is being evaluated for potential use to...
Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectives
May 08, 2024 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, May 08, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced the China...
Recce Pharmaceuticals Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
April 30, 2024 08:00 ET
|
Recce Pharmaceuticals
Independent Safety Committee approves increase of RECCE® 327 (R327) dose to 4,000mg intravenously (IV) over 30 minutes for six subjects, with dosing to start in near weeksR327 dosed at 3,000mg has...